Transforming growth factors type β1 and β2 are equipotent growth inhibitors of human breast cancer cell lines

G. Zugmaier, B. W. Ennis, B. Deschauer, D. Katz, C. Knabbe, G. Wilding, P. Daly, Marc E Lippman, R. B. Dickson

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

At least one member of the TGF-β family, TGF-β1, has been previously shown to inhibit the anchorage-independent growth of some human breast cancer cell lines (Knabbe et al., 1987; Arteaga et al., 1988). Members of the TGF-β family might, therefore, provide new strategies for breast cancer therapy. We have studied the inhibitory effects of TGF-β1 and TGF-β2 on the anchorage-independent growth of the estrogen receptor-negative cell lines MDA-MB-231, SK-BR-3, Hs578T, MDA-MB-468, and MDA-MB-468-S4 (an MDA-MB-468 clone not growth inhibited by EGF) and the estrogen receptor-positive cell lines MCF7, ZR-75-1, T-47D. TGF-β1 and TGF-β2 caused a 75-90% growth inhibition of MDA-MB-231, SK-BR-3, Hs578T, and MDA-MB-468 cells and a 50% growth inhibition of ZR-75-1 and early passage (< 100) MCF7 cells. T-47D cells responded to TGF-β only in serum-free conditions in the presence of IGF-1 or EGF. The growth of MDA-MB-468-S4 cells and late passage (> 500) MCF7 cells was not inhibited by TGF-β1 or TGF-β2. TGF-β-sensitive MCF7 and MDA-MB-231 cells did not respond to Muellerian inhibiting sustance (MIS), a TGF-β-related polypeptide. TGF-β1 and TGF-β2 were mutually competitive for receptor binding with a similar affinity (Kd 25-130 pM, 1,000-13,000 sites per cell). To determine the time course of the TGF-βeffect, an anchorage-dependent growth assay was carried out using MDA-MB-231 cells. Growth inhibition occurred at 6 days, and cell-cycle changes were seen 12 hr after the addition of TGF-β. Cells accumulated in the G1 phase and were thus inhibited from entering the S-phase. These data indicate that TGF-β is a potent growth inhibitor in most breast cancer cell lines and provide a basis for studying TGF-β effects in vivo.

Original languageEnglish
Pages (from-to)353-361
Number of pages9
JournalJournal of Cellular Physiology
Volume141
Issue number2
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Growth Inhibitors
Transforming Growth Factors
Cells
Breast Neoplasms
Cell Line
Growth
Estrogen Receptors
Competitive Binding
MCF-7 Cells
G1 Phase
S Phase
Epidermal Growth Factor Receptor
Epidermal Growth Factor
Assays
Cell Cycle
Estrogens
Clone Cells
Peptides

ASJC Scopus subject areas

  • Cell Biology
  • Clinical Biochemistry
  • Physiology

Cite this

Zugmaier, G., Ennis, B. W., Deschauer, B., Katz, D., Knabbe, C., Wilding, G., ... Dickson, R. B. (1989). Transforming growth factors type β1 and β2 are equipotent growth inhibitors of human breast cancer cell lines. Journal of Cellular Physiology, 141(2), 353-361.

Transforming growth factors type β1 and β2 are equipotent growth inhibitors of human breast cancer cell lines. / Zugmaier, G.; Ennis, B. W.; Deschauer, B.; Katz, D.; Knabbe, C.; Wilding, G.; Daly, P.; Lippman, Marc E; Dickson, R. B.

In: Journal of Cellular Physiology, Vol. 141, No. 2, 01.01.1989, p. 353-361.

Research output: Contribution to journalArticle

Zugmaier, G, Ennis, BW, Deschauer, B, Katz, D, Knabbe, C, Wilding, G, Daly, P, Lippman, ME & Dickson, RB 1989, 'Transforming growth factors type β1 and β2 are equipotent growth inhibitors of human breast cancer cell lines', Journal of Cellular Physiology, vol. 141, no. 2, pp. 353-361.
Zugmaier G, Ennis BW, Deschauer B, Katz D, Knabbe C, Wilding G et al. Transforming growth factors type β1 and β2 are equipotent growth inhibitors of human breast cancer cell lines. Journal of Cellular Physiology. 1989 Jan 1;141(2):353-361.
Zugmaier, G. ; Ennis, B. W. ; Deschauer, B. ; Katz, D. ; Knabbe, C. ; Wilding, G. ; Daly, P. ; Lippman, Marc E ; Dickson, R. B. / Transforming growth factors type β1 and β2 are equipotent growth inhibitors of human breast cancer cell lines. In: Journal of Cellular Physiology. 1989 ; Vol. 141, No. 2. pp. 353-361.
@article{843fa857df2e4ebba64a99fc1b4de993,
title = "Transforming growth factors type β1 and β2 are equipotent growth inhibitors of human breast cancer cell lines",
abstract = "At least one member of the TGF-β family, TGF-β1, has been previously shown to inhibit the anchorage-independent growth of some human breast cancer cell lines (Knabbe et al., 1987; Arteaga et al., 1988). Members of the TGF-β family might, therefore, provide new strategies for breast cancer therapy. We have studied the inhibitory effects of TGF-β1 and TGF-β2 on the anchorage-independent growth of the estrogen receptor-negative cell lines MDA-MB-231, SK-BR-3, Hs578T, MDA-MB-468, and MDA-MB-468-S4 (an MDA-MB-468 clone not growth inhibited by EGF) and the estrogen receptor-positive cell lines MCF7, ZR-75-1, T-47D. TGF-β1 and TGF-β2 caused a 75-90{\%} growth inhibition of MDA-MB-231, SK-BR-3, Hs578T, and MDA-MB-468 cells and a 50{\%} growth inhibition of ZR-75-1 and early passage (< 100) MCF7 cells. T-47D cells responded to TGF-β only in serum-free conditions in the presence of IGF-1 or EGF. The growth of MDA-MB-468-S4 cells and late passage (> 500) MCF7 cells was not inhibited by TGF-β1 or TGF-β2. TGF-β-sensitive MCF7 and MDA-MB-231 cells did not respond to Muellerian inhibiting sustance (MIS), a TGF-β-related polypeptide. TGF-β1 and TGF-β2 were mutually competitive for receptor binding with a similar affinity (Kd 25-130 pM, 1,000-13,000 sites per cell). To determine the time course of the TGF-βeffect, an anchorage-dependent growth assay was carried out using MDA-MB-231 cells. Growth inhibition occurred at 6 days, and cell-cycle changes were seen 12 hr after the addition of TGF-β. Cells accumulated in the G1 phase and were thus inhibited from entering the S-phase. These data indicate that TGF-β is a potent growth inhibitor in most breast cancer cell lines and provide a basis for studying TGF-β effects in vivo.",
author = "G. Zugmaier and Ennis, {B. W.} and B. Deschauer and D. Katz and C. Knabbe and G. Wilding and P. Daly and Lippman, {Marc E} and Dickson, {R. B.}",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "141",
pages = "353--361",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Transforming growth factors type β1 and β2 are equipotent growth inhibitors of human breast cancer cell lines

AU - Zugmaier, G.

AU - Ennis, B. W.

AU - Deschauer, B.

AU - Katz, D.

AU - Knabbe, C.

AU - Wilding, G.

AU - Daly, P.

AU - Lippman, Marc E

AU - Dickson, R. B.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - At least one member of the TGF-β family, TGF-β1, has been previously shown to inhibit the anchorage-independent growth of some human breast cancer cell lines (Knabbe et al., 1987; Arteaga et al., 1988). Members of the TGF-β family might, therefore, provide new strategies for breast cancer therapy. We have studied the inhibitory effects of TGF-β1 and TGF-β2 on the anchorage-independent growth of the estrogen receptor-negative cell lines MDA-MB-231, SK-BR-3, Hs578T, MDA-MB-468, and MDA-MB-468-S4 (an MDA-MB-468 clone not growth inhibited by EGF) and the estrogen receptor-positive cell lines MCF7, ZR-75-1, T-47D. TGF-β1 and TGF-β2 caused a 75-90% growth inhibition of MDA-MB-231, SK-BR-3, Hs578T, and MDA-MB-468 cells and a 50% growth inhibition of ZR-75-1 and early passage (< 100) MCF7 cells. T-47D cells responded to TGF-β only in serum-free conditions in the presence of IGF-1 or EGF. The growth of MDA-MB-468-S4 cells and late passage (> 500) MCF7 cells was not inhibited by TGF-β1 or TGF-β2. TGF-β-sensitive MCF7 and MDA-MB-231 cells did not respond to Muellerian inhibiting sustance (MIS), a TGF-β-related polypeptide. TGF-β1 and TGF-β2 were mutually competitive for receptor binding with a similar affinity (Kd 25-130 pM, 1,000-13,000 sites per cell). To determine the time course of the TGF-βeffect, an anchorage-dependent growth assay was carried out using MDA-MB-231 cells. Growth inhibition occurred at 6 days, and cell-cycle changes were seen 12 hr after the addition of TGF-β. Cells accumulated in the G1 phase and were thus inhibited from entering the S-phase. These data indicate that TGF-β is a potent growth inhibitor in most breast cancer cell lines and provide a basis for studying TGF-β effects in vivo.

AB - At least one member of the TGF-β family, TGF-β1, has been previously shown to inhibit the anchorage-independent growth of some human breast cancer cell lines (Knabbe et al., 1987; Arteaga et al., 1988). Members of the TGF-β family might, therefore, provide new strategies for breast cancer therapy. We have studied the inhibitory effects of TGF-β1 and TGF-β2 on the anchorage-independent growth of the estrogen receptor-negative cell lines MDA-MB-231, SK-BR-3, Hs578T, MDA-MB-468, and MDA-MB-468-S4 (an MDA-MB-468 clone not growth inhibited by EGF) and the estrogen receptor-positive cell lines MCF7, ZR-75-1, T-47D. TGF-β1 and TGF-β2 caused a 75-90% growth inhibition of MDA-MB-231, SK-BR-3, Hs578T, and MDA-MB-468 cells and a 50% growth inhibition of ZR-75-1 and early passage (< 100) MCF7 cells. T-47D cells responded to TGF-β only in serum-free conditions in the presence of IGF-1 or EGF. The growth of MDA-MB-468-S4 cells and late passage (> 500) MCF7 cells was not inhibited by TGF-β1 or TGF-β2. TGF-β-sensitive MCF7 and MDA-MB-231 cells did not respond to Muellerian inhibiting sustance (MIS), a TGF-β-related polypeptide. TGF-β1 and TGF-β2 were mutually competitive for receptor binding with a similar affinity (Kd 25-130 pM, 1,000-13,000 sites per cell). To determine the time course of the TGF-βeffect, an anchorage-dependent growth assay was carried out using MDA-MB-231 cells. Growth inhibition occurred at 6 days, and cell-cycle changes were seen 12 hr after the addition of TGF-β. Cells accumulated in the G1 phase and were thus inhibited from entering the S-phase. These data indicate that TGF-β is a potent growth inhibitor in most breast cancer cell lines and provide a basis for studying TGF-β effects in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0024442893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024442893&partnerID=8YFLogxK

M3 - Article

C2 - 2808542

AN - SCOPUS:0024442893

VL - 141

SP - 353

EP - 361

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

IS - 2

ER -